Provided by Tiger Trade Technology Pte. Ltd.

ACADIA Pharmaceuticals

20.75
-0.7200-3.35%
Post-market: 20.800.0485+0.23%17:27 EDT
Volume:1.22M
Turnover:25.37M
Market Cap:3.54B
PE:9.02
High:21.42
Open:21.25
Low:20.75
Close:21.47
52wk High:28.35
52wk Low:13.40
Shares:170.49M
Float Shares:115.85M
Volume Ratio:0.57
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.30
EPS(LYR):2.30
ROE:39.89%
ROA:4.76%
PB:2.88
PE(LYR):9.02

Loading ...

RBC Raises Price Target on ACADIA Pharmaceuticals to $35 From $33, Keeps Outperform Rating

MT Newswires Live
·
Jan 20

Neuren Shares Rise on Higher Daybue Sales Forecast

Dow Jones
·
Jan 14

ACADIA Pharmaceuticals Clarifies Form 8-K Disclosure Treatment

TIPRANKS
·
Jan 14

ACADIA Pharmaceuticals Inc - Anticipates 2025 Net Sales to Exceed $1 Bln - SEC Filing

THOMSON REUTERS
·
Jan 14

Acadia Pharmaceuticals projects $1.7 billion in net sales by 2028

Reuters
·
Jan 13

ACADIA Pharmaceuticals Provides Business and Pipeline Updates at 44TH Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS
·
Jan 13

Analysts Conflicted on These Healthcare Names: Cormedix (CRMD), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
Jan 13

RBC Lifts Price Target on ACADIA Pharmaceuticals to $33 From $32, Keeps Outperform Rating

MT Newswires Live
·
Jan 08

ACADIA Pharmaceuticals Is Maintained at Buy by UBS

Dow Jones
·
Jan 07

UBS Adjusts Price Target on ACADIA Pharmaceuticals to $40 From $35, Maintains Buy Rating

MT Newswires Live
·
Jan 06

U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure

Reuters
·
Jan 06

FDA Expands Indication for Blood Disorder Drug, ACADIA Pharmaceuticals' Stock Soars

Deep News
·
Dec 24, 2025

Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 12-Month Share Price Rally

Simply Wall St.
·
Dec 21, 2025

U.S. RESEARCH ROUNDUP-Autozone, Coursera, Lennar

Reuters
·
Dec 18, 2025

ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 16, 2025

BUZZ-Australia's Neuren soars as partner Acadia wins FDA nod for Rett syndrome treatment

Reuters
·
Dec 15, 2025

FDA Approves Acadia Pharmaceuticals' DAYBUE STIX for Rett Syndrome

Reuters
·
Dec 12, 2025

ACADIA Pharmaceuticals Inc - Daybue Stix Will Be Available on a Limited Basis Starting in Q1 2026 and More Broadly Early in Q2 2026

THOMSON REUTERS
·
Dec 12, 2025

ACADIA Pharmaceuticals Announces FDA Approval of Daybue® Stix (Trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

THOMSON REUTERS
·
Dec 12, 2025

ACADIA Pharmaceuticals Is Maintained at Hold by Stifel

Dow Jones
·
Dec 11, 2025